[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-370203-105":59,"doc-detail-370203-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","immunotherapy-in-gastric-cancer-a-systematic-review","Immunotherapy in gastric cancer - A systematic review","","Gastric cancer is a major cause of cancer incidence and mortality worldwide. Immunotherapy has become a promising treatment strategy, aiming to improve clinical outcomes while addressing limits of conventional therapies. This systematic review summarizes advances in immune-based approaches for gastric cancer, focusing on adoptive cell therapy, cancer vaccines, and immune checkpoint inhibitors. PubMed-identified key studies were reviewed, outcomes related to disease progression and survival were analyzed, and efficacy—especially pembrolizumab—was assessed alongside safety and resistance mechanisms.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/immunotherapy-in-gastric-cancer-a-systematic-review/370203/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/immunotherapy-in-gastric-cancer-a-systematic-review/370203.png","ImageObject",300,407,{"name":92,"@type":93},"Finn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What treatment approaches are covered in this systematic review for gastric cancer immunotherapy?","Question",{"text":112,"@type":113},"The review covers adoptive cell therapy (ACT), cancer vaccines, and immune checkpoint inhibitors (ICI). It focuses on immune-based therapeutic advances in gastric cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What did the review find regarding efficacy, particularly for pembrolizumab?",{"text":117,"@type":113},"After screening 236 studies, results showed promising efficacy for immunotherapy, especially pembrolizumab. Studies reported improved overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) with pembrolizumab alone or combined with other modalities.",{"name":119,"@type":110,"acceptedAnswer":120},"How did the review evaluate safety and what further research is suggested?",{"text":121,"@type":113},"Safety analysis indicated that immunotherapy was mostly well-tolerated, with manageable adverse events and relatively good safety profiles. Further research is needed to better understand tumor resistance mechanisms and identify predictive biomarkers to optimize treatment.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},370203,1790238527,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":14,"preview_urls":145},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","ONCOLOGY RESEARCH 2025 33(2): 263-281 REVIEW  \nImmunotherapy in gastric cancer—A systematic review  \nMARTA SANTOS 1; DIANA MARTINS 1,2,3,4; FERNANDO MENDES 1,2,3,4,5,*  \n1 Polytechnic University of Coimbra, ESTESC, UCPCBL, Rua 5 de Outubro, SM Bispo, Apartado, Coimbra, 3046-854, Portugal  \n2 H&TRC–Health & Technology Research Center, Coimbra Health School, Polytechnic University of Coimbra, Coimbra, 3046-854, Portugal  \n3 Coimbra Institute for Clinical and Biomedical Research (iCBR) Area of Environment Genetics and Oncobiology (CIMAGO), Biophysics Institute of Faculty of Medicine, University of Coimbra, Coimbra, 3000-548, Portugal  \n4 Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, Coimbra, 3000-548, Portugal  \n5 European Association of Biomedical Scientists, Brussels, 1000, Belgium  \nKey words: Gastric neoplasm, Target therapy, Immune checkpoint inhibitors (ICI), Adoptive cell therapy (ACT), Cancer vaccines  \nAbstract: Background: Gastric Cancer (GC) is the 5th most prevalent and 4th most deadly neoplasm globally.  \nImmunotherapy has emerged as a promising treatment approach in GC, potentially improving positive clinical outcomes while addressing the limitations of conventional therapies. GC immunotherapy modalities consist of adoptive cell therapy (ACT), cancer vaccines, and immune checkpoint inhibitors (ICI) . Objectives: This systematic review aims to provide an overview of the advances in immune-based therapeutic approaches in GC, highlighting the potential of this therapy as a strategy for GC treatment. Methods: Key studies investigating several immunotherapeutic agents and combination therapies were searched in PUBMED and included in this study. Speciﬁc cancer outcomes related to disease progression or survival were analyzed. Results: After screening 236 studies, the results revealed that immunotherapy, particularly the ICI pembrolizumab, demonstrated promising efﬁcacy in the treatment of GC, as several studies reported improved OS, PFS, and objective response rate with the use of pembrolizumab alone or in combination with other treatment modalities. Conclusion: Safety analysis showed that immunotherapy was mostly well-tolerated, with manageable adverse events and relatively good safety proﬁles.  \nNonetheless, further research is required to understand the mechanisms of tumor resistance better and identify  \npredictive biomarkers that can direct treatment optimization.  \nAbbreviations  \nACT  \nAE  \nCAR CPS CR CTLA-4  \ndMMR  \nDOR  \nEGFR  \nEMT  \nFDA  \nG/GEJ  \nAdoptive Cell Therapy Adverse Event  \nChimeric Antigen Receptor Combined Positive Score Complete Response  \nCytotoxic T-lymphocyte-associated antigen 4  \nDeﬁcient in DNA Mismatch Repair Duration of Response  \nEpidermal Growth Factor Receptor Epithelial to Mesenchymal Transition Food and Drug Administration Gastric/Gastroesophageal Junction  \n*Address correspondence to: Fernando Mendes, [fjmendes@estesc.ipc.pt](fjmendes@estesc.ipc.pt)  \nReceived: 26 March 2024; Accepted: 22 November 2024;  \nPublished: 16 January 2025  \nHBVHCC HER-2  \nHPV  \nIC  \nICI  \nmAb  \nMHC  \nmRNA  \nMSI-H  \nMSI-H/dMMR  \nNK  \nORR  \nOS  \nPD PD-1 PD-L1  \nHepatitis B Virus  \nHepatocellular Carcinoma  \nHuman Epidermal Growth Factor Receptortype 2  \nHuman Papilloma Virus Immune Checkpoint  \nImmune Checkpoint Inhibitor Monoclonal Antibody  \nMajor Histocompatibility Complex Messenger RNA  \nMicrosatellite Instability High Deﬁcient in DNA Mismatch Repair and High Microsatellite Instability Natural Killer  \nObjective Response Rate  \nOverall Survival Progressive Disease  \nProgrammed Cell Death 1  \nProgrammed Death-Ligand 1  \nDoi: [10.32604/or.2024.052207 www.techscience.com/journal/or](10.32604/or.2024.052207 www.techscience.com/journal/or)  \nCopyright © 2025 The Authors. Published by Tech Science Press.  \nThis work is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided ","cbCaijXqAMV1qqlC","https://ap.wps.com/l/cbCaijXqAMV1qqlC","pdf",17054521,"English","# Introduction\n## Diagnosis and risk factors\n# Background and objectives\n# Methods\n## Study selection in PubMed\n# Results\n## Efficacy of immune checkpoint inhibitors\n# Conclusion\n## Safety and future research directions","[{\"question\":\"What treatment approaches are covered in this systematic review for gastric cancer immunotherapy?\",\"answer\":\"The review covers adoptive cell therapy (ACT), cancer vaccines, and immune checkpoint inhibitors (ICI). It focuses on immune-based therapeutic advances in gastric cancer.\"},{\"question\":\"What did the review find regarding efficacy, particularly for pembrolizumab?\",\"answer\":\"After screening 236 studies, results showed promising efficacy for immunotherapy, especially pembrolizumab. Studies reported improved overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) with pembrolizumab alone or combined with other modalities.\"},{\"question\":\"How did the review evaluate safety and what further research is suggested?\",\"answer\":\"Safety analysis indicated that immunotherapy was mostly well-tolerated, with manageable adverse events and relatively good safety profiles. Further research is needed to better understand tumor resistance mechanisms and identify predictive biomarkers to optimize treatment.\"}]","Immunotherapy in gastric cancer - A systematic review | PDF",1790187339,48,[146,150],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/83f73be405a3de2f4a6ebf67ce123e50.webp",983,1390,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/477f3a0bc0215e3b346c67d35737f423.webp",982,1388]